Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

Phase 1 Unknown 21 enrolled Christine Lau, MD National Heart, Lung, and Blood Institute (NHLBI) · collab

SequentialOpen-labelTreatment

Summary

This study will evaluate the maximum safe dose and duration of regadenoson (Lexiscan) that can be given to people who are having a lung transplant. Regadenoson will be given as a continuous IV infusion. All participants in the study will receive a regadenoson infusion beginning in the operating room during the lung transplant procedure. Participants will be assigned a certain dose of regadenoson to be given over a 12 or 24 hour period.

Timeline

Start: 2017-11-30
Primary completion: 2021-08-01
Completion: 2022-08-01

Publications

Lau CL, Beller JP, Boys JA, Zhao Y, Phillips J, Cosner M, Conaway MR, Petroni G, Charles EJ, Mehaffey JH, Mannem HC, Kron IL, Krupnick AS, Linden J. Adenosine A2A receptor agonist (regadenoson) in human lung transplantation. J Heart Lung Transplant. 2020 Jun;39(6):563-570. doi: 10.1016/j.healun.2020.02.003. Epub 2020 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Regadenoson	Diagnostic / imaging agent	1.44 ug/kg	Intravenous

Indications

No indication recorded.